Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial - 21/08/11
Doi : 10.1016/j.jaad.2005.06.053
Steven R. Feldman, MD, PhD a, ⁎ 
, Alexa Boer Kimball, MD, MPH b, Gerald G. Krueger, MD c, J. Michael Woolley, PhD d, Deepa Lalla, PhD d, Angelika Jahreis, MD d
, Alexa Boer Kimball, MD, MPH b, Gerald G. Krueger, MD c, J. Michael Woolley, PhD d, Deepa Lalla, PhD d, Angelika Jahreis, MD d a From the Wake Forest University School of Medicine, Winston Salem, North Carolina
b Massachusetts General and Brigham and Women’s Hospitals
c University of Utah Health Sciences Center
d Amgen, Thousand Oaks, California
Reprint requests: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157-1071.Winston Salem, North Carolina; Boston, Massachusetts; Salt Lake City, Utah; and Thousand Oaks, California
Abstract |
In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients’ health-related quality of life.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: Amgen Inc and its subsidiaries. Disclosure: Dr Feldman has received consulting, research, and speaking support from Amgen. Dr Kimball has served as consultant and received honoraria for speaking from Amgen and was supported for participating in this study along with other research studies supported by Amgen. Dr Krueger acted as the principal investigator for the portion of this trial that was conducted at the University of Utah. During the past 5 years he has not served on the Amgen Board of Advisors for etanercept, but has acted on an ad hoc basis as an advisor and is an Amgen-sponsored speaker. He does not own stock or have other equity ownership, stock options, patent licensing arrangements, or payments for conducting or publicizing the study. He has similar positions for companies with competing products. Drs Woolley and Jahreis are employees of Amgen Inc. Dr Lalla is a former employee of Amgen Inc. Previously presented in abstract and poster forms only at the American Academy of Dermatology Summer Academy Meeting, July 25, 2003, Chicago, IL; the American Academy of Dermatology Annual Meeting, February 6, 2004, Washington, DC; and the Society for Investigative Dermatology Meeting, April 24, 2004, Providence, RI. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 53 - N° 5
P. 887-889 - novembre 2005 Retour au numéro
Article précédent
- Dermoscopy of the nail bed and matrix to assess melanonychia striata
- Sergio H. Hirata, Sergio Yamada, Fernando A. Almeida, Jane Tomomori-Yamashita, Mauro Y. Enokihara, Francisco M. Paschoal, Milvia M. Enokihara, Cinthia M. Outi, Nilceo S. Michalany
- Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: Portents of an old scourge
- Wing-Yan Au, Yok-Lam Kwong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?